Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10862)	7/22/1999 11:24:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Peter, you stated>>>>>>>>BTW, I very much doubt the purchaser got a peek at the results of the trial. The cynical might even ask why the company would sell stock now at under $6 if they were confident that the trial results would be favorable and they could sell stock at some multiple of that a few months from now.<<<<<< Do reserve saying such things just about Xoma? NO MATTER WHAT THE RESULTS THEY STILL HAVE TO GET THROUGH A WHIMSICAL FDA APPROVAL PROCESS. That, my friend makes Biotechs extremely risky, no slam dunks ANYWHERE in my opinion.

To: Biomaven who wrote (10862)	7/22/1999 11:25:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

For sometime I thought XOMA had already unblinded the trial. With the news I now think they probably did not until the stock deal was done. Not looking first would assure no leaks or at least make it more difficult for others to successful charge there had been leaks. On Yahoo I questioned why XOMA would sell stock now. I know what I would have done, but fully understand why XOMA chooses to do what they did. It is a more conservative stance and they are not about to bet the survival of the company on the trial results no matter how good they think they might be. While the stock would tank if the results were not good, BPI & LBP would still be platforms worth further development, IMO. The Allergan news yesterday of a FDA advisory panel turndown for a cyclosporin product should mean greater incentive to move forward on research and development of a BPI/antibiotic product. Let the unblinding begin!